Lv2
170 积分 2022-04-11 加入
Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study
21小时前
待确认
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
1天前
已完结
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
1天前
已完结
KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD)
11天前
已完结
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
11天前
已完结
Interstitial Lung Disease
22天前
已完结
Meta-analysis of rituximab treatment of systemic sclerosis related interstitial lung disease
1个月前
已关闭
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Multi-Centre Randomised Controlled Trial
1个月前
已完结
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
1个月前
已完结
Abstract Supplement ACR Convergence 2022
2个月前
已完结
皖公网安备34019202002308
